Laboratory News and Research

RSS

New research project to genetically discriminate "identical" monozygotic twins

Eurofins Scientific, a European leader in Genomics Services, Forensics and Paternity Testing, announces a milestone in genetic and forensic research.

10 Dec 2013

Study finds large degree of genetic variation amongst M. tuberculosis in humans in Zambia

In Zambia, the incidence of all forms of human tuberculosis is estimated to be 444 per 100,000. There is also a high incidence of HIV and AIDS in the country. In the Kafue area, a high incidence of Mycobacterium bovis in both cattle and the Kafue lechwe antilope has been detected. This bacterium can infect humans and has been found in humans in the studied region of Namwala. Mycobacterium tuberculosis, which is the main cause of human tuberculosis, has also been detected in cattle in this region.

10 Dec 2013

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

Restricting the use of antibiotics is unlikely to stop the spread of drug resistance in typhoid fever, according to a study funded by the Wellcome Trust and published in the journal eLife.

10 Dec 2013

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

10 Dec 2013

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.

10 Dec 2013

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology.

10 Dec 2013

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

A team led by a longtime Oregon Health & Science University researcher has demonstrated in mice what could be a revolutionary new technique to cure a wide range of human diseases - from cystic fibrosis to cataracts to Alzheimer's disease - that are caused by "misfolded" protein molecules.

9 Dec 2013

Equations help explain key parameters of stents that combat artherosclerosis

Coronary heart disease accounts for 18% of deaths in the United States every year. The disease results from a blockage of one or more arteries that supply blood to the heart muscle.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

TAU researchers discover gene that may predict human responses to specific antidepressants

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants, but they don't work for everyone. What's more, patients must often try several different SSRI medications, each with a different set of side effects, before finding one that is effective.

9 Dec 2013

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

9 Dec 2013

Growing cord blood stem cells in lab before transplant boosts survival, study finds

Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers.

9 Dec 2013

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

Atonomics reaches agreement to advance development of diagnostic test for lifestyle diseases

Atonomics announces today that it has entered into an agreement with Omron Healthcare, which will enable Atonomics to advance the development of the AtolyzerConsumer device for advanced diagnostic testing of lifestyle diseases in a consumer pharmacy setting. As part of the transaction Omron Healthcare is taking a minority equity stake in Atonomics.

9 Dec 2013

NYSCF, PersonalGenomes.org partner to identify genetic contributions to disease development

Today, the New York Stem Cell Foundation Research Institute and PersonalGenomes.org announced a partnership to identify genetic and environmental contributions to trait and disease development. Cell lines generated by NYSCF will complement genomic data and medical histories contributed by participants in the Harvard Personal Genome Project, creating a unique and powerful resource to help researchers identify causes of disease.

9 Dec 2013

Laboratory News and Research

New research project to genetically discriminate "identical" monozygotic twins

Study finds large degree of genetic variation amongst M. tuberculosis in humans in Zambia

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

Equations help explain key parameters of stents that combat artherosclerosis

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

TAU researchers discover gene that may predict human responses to specific antidepressants

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Growing cord blood stem cells in lab before transplant boosts survival, study finds

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

Atonomics reaches agreement to advance development of diagnostic test for lifestyle diseases

NYSCF, PersonalGenomes.org partner to identify genetic contributions to disease development

Pittcon 2024 - Advancing Science on the West Coast eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics